People: BioSante Pharmaceuticals Inc (BPAX.A)

BPAX.A on American Stock Exchange

1.14USD
1:52pm EDT
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.14
Open
$1.14
Day's High
$1.14
Day's Low
$1.14
Volume
400
Avg. Vol
2,040
52-wk High
$3.40
52-wk Low
$1.02

Search Stocks

Summary

Name Age Since Current Position

Louis Sullivan

 79 1998 Independent Chairman of the Board

Stephen Simes

 60 1998 Vice Chairman of the Board, President, Chief Executive Officer

Phillip Donenberg

 51 2010 Chief Financial Officer, Senior Vice President - Finance, Secretary

Fred Holubow

 73 1999 Independent Director

Ross Mangano

 66 1999 Independent Director

John Potts

 80 2009 Independent Director

Edward Rosenow

 77 1997 Independent Director

Stephen Sherwin

 64 2009 Independent Director
» Insider Trading

Biographies

Name Description

Louis Sullivan

 Dr. The Honorable Louis W. Sullivan, M.D., is Independent Chairman of the Board of BioSante Pharmaceuticals Inc. He has been Chairman of the Board since 1998 and has been a director of the company since its formation. Dr. Sullivan served as Secretary of Health and Human Services in the cabinet of President George H.W. Bush from 1989 to 1993. Since retiring from the Bush Administration, Dr. Sullivan has been associated with the Morehouse School of Medicine in Atlanta, Georgia. Currently, he serves as President Emeritus and he previously served as President and Dean of the School from 1981 to 1985 and as President from 1985 to 1989 and from 1993 to 2002. Dr. Sullivan serves on the board of directors of Henry Schein Inc., United Therapeutics Corporation and Emergent BioSolutions Inc. Dr. Sullivan also serves as chairman of the National Health Museum in Atlanta, Georgia and as chairman of the Sullivan Alliance to Increase Diversity in the Health Profession. Dr. Sullivan previously served on the boards of directors of Inhibitex, Inc., 3M Corp., Bristol-Myers Squibb Company, Cigna Corporation and Georgia Pacific Corp.

Stephen Simes

 Mr. Stephen M. Simes is Vice Chairman of the Board, President, Chief Executive Officer of BioSante Pharmaceuticals Inc. since 1998. From 1994 to 1997, Mr. Simes was President, Chief Executive Officer and a Director of Unimed Pharmaceuticals, Inc. (currently a wholly owned subsidiary of Abbott Laboratories), a company with a product focus on infectious diseases, AIDS, endocrinology and oncology. From 1989 to 1993, Mr. Simes was Chairman, President and Chief Executive Officer of Gynex Pharmaceuticals, Inc., a company which concentrated on the AIDS, endocrinology, urology and growth disorders markets. In 1993, Gynex was acquired by Savient Pharmaceuticals Inc. (formerly Bio-Technology General Corp.), and from 1993 to 1994, Mr. Simes served as Senior Vice President and director of Savient Pharmaceuticals Inc. Mr. Simes’s career in the pharmaceutical industry started in 1974 with G.D. Searle & Co. (now a part of Pfizer Inc.). Mr. Simes currently serves as designee on the board of directors of Ceregene, Inc., a privately-held biotechnology company focused on the treatment of neurodegenerative disorders.

Phillip Donenberg

 Mr. Phillip B. Donenberg, CPA, is Chief Financial Officer, Senior Vice President - Finance, Secretary of BioSante Pharmaceuticals Inc. He has served as Company's Senior Vice President of Finance since August 2010 and Chief Financial Officer and Secretary since 1998. Before joining company, Mr. Donenberg was Controller of Unimed Pharmaceuticals, Inc. (currently a wholly owned subsidiary of Abbott Laboratories) from 1995 to 1998. Prior to Unimed Pharmaceuticals, Inc., Mr. Donenberg held similar positions with other pharmaceutical companies, including Gynex Pharmaceuticals, Inc. (currently Savient Pharmaceuticals, Inc.), Applied NeuroSolutions, Inc. (formerly Molecular Geriatrics Corporation) and Xtramedics, Inc.

Fred Holubow

 Mr. Fred Holubow is Independent Director of BioSante Pharmaceuticals Inc., since 1999. Mr. Holubow is the Principal of Petard Risk Analysis and a General Partner of Starbow Partners. From 2001 to December 2011, Mr. Holubow served as a Managing Director of William Harris Investors, Inc., a registered investment advisory firm. From 1982 to 2001, Mr. Holubow served as Vice President of Pegasus Associates, a registered investment advisory firm he co-founded. He specializes in analyzing and investing in pharmaceutical and biotechnology companies. Mr. Holubow previously served on the boards of directors of Micrus Endovascular Corporation, ThermoRetec Corporation, Savient Pharmaceuticals, Inc. (formerly Bio-Technology General Corp.), Gynex Pharmaceuticals, Inc. and Unimed Pharmaceuticals, Inc.

Ross Mangano

 Mr. Ross Mangano is Independent Director of BioSante Pharmaceuticals Inc., since 1999. Mr. Mangano has been the President and a director of Oliver Estate, Inc., a management company specializing in investments in public and private companies, since 1971. Mr. Mangano in the past has served on the boards of directors of Cerprobe Corporation, Tower Federal Savings & Loan, Cypress Communications, Inc. and Mego Financial Corp.

John Potts

 Dr. John T. Potts, Jr., M.D., is Independent Director of BioSante Pharmaceuticals Inc., since October 2009, when he was elected to the Board of Directors in connection with the company's merger with Cell Genesys, Inc. His career spans more than 40 years of service in science and medicine. Dr. Potts is currently the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School. After medical training at the University of Pennsylvania, he did his internship and residency at Massachusetts General Hospital (MGH) from 1957 to 1959, then went to the National Institutes of Health (NIH) to work with Nobel laureate Christian Anfinsen in protein chemistry. Dr. Potts remained at the NIH from 1959 to 1968, when he returned to the MGH as chief of endocrinology. He served as chairman of the Department of Medicine and physician-in-chief from 1981 to 1996. In his role as director of research from 1995 to 2004, Dr. Potts was responsible for developing strategies for preserving and strengthening the scientific research effort at MGH, an endeavor which he continues to the present. The author or co-author of more than 500 scientific publications, he is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. Dr. Potts is a director of Zeltiq Aesthetics, a founder of Radius Health, Inc., and a member of the Scientific Advisory Boards of Radius Health, Inc. and MPM Capital. During the past five years, Dr. Potts previously served on the boards of directors of Cell Genesys, Inc. and Celltaxsys.

Edward Rosenow

 Dr. Edward C. Rosenow, III, M.D., is Independent Director of BioSante Pharmaceuticals Inc., since 1997. Dr. Rosenow is a Master Fellow of the American College of Physicians as well as Master Fellow of the American College of Chest Physicians. Dr. Rosenow was the Arthur M. and Gladys D. Gray Professor of Medicine at the Mayo Clinic from 1988 until his retirement in 1996. Beginning with his residency in 1960, Dr. Rosenow has worked at the Mayo Clinic in many professional capacities including as a Consultant in Internal Medicine (Thoracic Diseases) from 1966 to 1996, an Assistant Professor, Associate Professor and Professor of Medicine at the Mayo Clinic Medical School, President of the Mayo Clinic Staff in 1986, and Chair of the Division of Pulmonary and Critical Care Medicine from 1987 to 1994. In 1994, Dr. Rosenow received the Mayo Distinguished Clinician Award. Dr. Rosenow also has served as a consultant to NASA, space station FREEDOM at the Johnson Space Center in Houston, Texas from 1989 to 1990 and as the President of the American College of Chest Physicians from 1989 to 1990. In 1998, he received the Mayo Distinguished Alumnus Award. In 2007, Dr. Rosenow was awarded a named professorship, the Edward C. Rosenow III, M.D. Professorship in the Art of Medicine at the Mayo Clinic School of Medicine, given by Bruce, Martha and Zylpha Clinton. In 2009, he received the Plummer Society Award for Excellence in Medicine.

Stephen Sherwin

 Dr. Stephen A. Sherwin, M.D., is Independent Director of BioSante Pharmaceuticals Inc., since October 2009 when he was elected to board of directors in connection with merger with Cell Genesys, Inc. Dr. Sherwin is currently chairman of the board of directors of Ceregene, Inc., a company which he co-founded in 2001 and a Clinical Professor of Medicine at the University of California, San Francisco. Dr. Sherwin served as chief executive officer and a director of Cell Genesys, Inc. from the beginning of company operations in 1990 to October 2009 and as chairman of the board from 1994 to October 2009. From 1983 to 1990, Dr. Sherwin held various positions at Genentech, Inc., most recently as vice president of clinical research. Prior to 1983, Dr. Sherwin was on the staff of the National Cancer Institute. Dr. Sherwin also was a co-founder of Abgenix, Inc, an antibody company, which was acquired by Amgen in 2006. He also is a director of Biogen Idec, Inc., Neurocrine Biosciences, Inc. and Rigel Pharmaceuticals, Inc. and currently chairman emeritus of the Biotechnology Industry Organization (BIO). Dr. Sherwin holds a B.A. in biology from Yale University, an M.D. from Harvard Medical School and is board-certified in internal medicine and medical oncology. During the past five years, Dr. Sherwin previously served on the board of directors of Cell Genesys, Inc.

Basic Compensation

Name Fiscal Year Total

Louis Sullivan

 --

Stephen Simes

 1,533,430

Phillip Donenberg

 746,625

Fred Holubow

 --

Ross Mangano

 --

John Potts

 --

Edward Rosenow

 --

Stephen Sherwin

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

Louis Sullivan

 0 0

Stephen Simes

 632,831 1,610,954

Phillip Donenberg

 276,640 714,169

Fred Holubow

 0 0

Ross Mangano

 0 0

John Potts

 0 0

Edward Rosenow

 0 0

Stephen Sherwin

 0 0

Insider Trading

Name Shares Traded Price

ROSENOW EDWARD C III

 3,000 $2.37

SULLIVAN LOUIS W

 10,000 $2.67

MANGANO ROSS J

 25,000 $2.40

DONENBERG PHILLIP BRIAN

 1,000 $2.23

MANGANO ROSS J

 80,000 $2.21

DONENBERG PHILLIP BRIAN

 1,000 $2.19
» Full list on Insider Trading
Search Stocks